Inhibition	NN
of	IN
HSP27	NN
blocks	VBZ
fibrosis	NN
development	NN
and	CC
EMT	NN
features	NNS
by	IN
promoting	VBG
Snail	NN
degradation	NN
.	.

Idiopathic	JJ
pulmonary	JJ
fibrosis	NN
(	(
IPF	NN
)	)
is	VBZ
a	DT
devastating	JJ
disease	NN
characterized	VBN
by	IN
myofibroblast	NN
proliferation	NN
.	.

Transition	NN
of	IN
epithelial/mesothelial	JJ
cells	NNS
into	IN
myofibroblasts	NNS
[	(
epithelial-to-mesenchymal	JJ
transition	NN
(	(
EMT	NN
)	)
]	)
occurs	VBZ
under	IN
the	DT
influence	NN
of	IN
transforming	VBG
growth	NN
factor	NN
(	(
TGF	NN
)	)
-	:
b1	NN
,	,
with	IN
Snail	NN
being	VBG
a	DT
major	JJ
transcription	NN
factor	NN
.	.

We	PRP
study	VBP
here	RB
the	DT
role	NN
of	IN
the	DT
heat-shock	JJ
protein	NN
HSP27	NN
in	IN
fibrogenesis	NN
and	CC
EMT	NN
.	.

In	FW
vitro	FW
,	,
we	PRP
have	VBP
up	RP
-	:
and	CC
down-modulated	VBN
HSP27	NN
expression	NN
in	IN
mesothelial	JJ
and	CC
epithelial	JJ
cell	NN
lines	NNS
and	CC
studied	VBD
the	DT
expression	NN
of	IN
different	JJ
EMT	NN
markers	NNS
induced	VBN
by	IN
TGF-b1	NN
.	.

In	FW
vivo	FW
,	,
we	PRP
inhibited	VBD
HSP27	NN
with	IN
the	DT
antisense	JJ
oligonucleotide	NN
OGX-427	NN
(	(
in	IN
phase	NN
II	CD
clinical	JJ
trials	NNS
as	IN
anticancer	JJ
agent	NN
)	)
in	IN
our	PRP$
rat	NN
subpleural/pulmonary	JJ
fibrosis	NN
models	NNS
.	.

We	PRP
demonstrate	VBP
that	IN
HSP27	NN
is	VBZ
strongly	RB
expressed	VBN
during	IN
the	DT
fibrotic	JJ
process	NN
in	IN
patients	NNS
with	IN
IPF	NN
and	CC
in	IN
different	JJ
in	FW
vivo	FW
models	NNS
.	.

We	PRP
showed	VBD
that	IN
HSP27	NN
binds	VBZ
to	TO
and	CC
stabilizes	VBZ
Snail	NN
and	CC
consequently	RB
induces	VBZ
EMT	NNP
.	.

Conversely	RB
,	,
HSP27	NN
knockdown	NN
leads	VBZ
to	TO
Snail	NN
proteasomal	JJ
degradation	NN
,	,
thus	RB
inhibiting	VBG
TGF-b1-induced	JJ
EMT	NN
.	.

Inhibition	NN
of	IN
HSP27	NN
with	IN
OGX-427	NN
efficiently	RB
blocks	VBZ
EMT	NN
and	CC
fibrosis	NN
development	NN
.	.

Controls	NNP
in	FW
vivo	FW
were	VBD
an	DT
empty	JJ
adenovirus	NN
that	WDT
did	VBD
not	RB
induce	VB
fibrosis	NN
and	CC
a	DT
control	NN
antisense	JJ
oligonucleotide	NN
.	.

The	DT
present	JJ
work	NN
opens	VBZ
the	DT
possibility	NN
of	IN
a	DT
new	JJ
therapeutic	JJ
use	NN
for	IN
HSP27	NN
inhibitors	NNS
against	IN
IPF	NNP
,	,
for	IN
which	WDT
there	EX
is	VBZ
no	DT
conclusively	RB
effective	JJ
treatment	NN
.	.

